An increased concentration of lipids (triglycerides consisting of chylomicrons and very-low-density lipoproteins) in the blood is referred to as hyperlipidemia or lipemia. It is not uncommon to observe lipemia in postprandial specimens and in specimens drawn from patients with diabetes or those receiving parenteral nutrition with intralipid emulsion [6]. Lipemia interferes primarily with Hb measurement and results in falsely higher Hb, MCH, and MCHC [7]. A discrepancy between Hb and Hct with an elevated MCHC concentration is a useful indicator of the effect of lipemia. An analyzer-generated flag of turbidity or Hb interference is also helpful. Lipemic blood appears milky turbid upon visual inspection of the specimen that had time to settle or was centrifuged (Fig. 1). Microscopic examination of the blood smear is helpful in ruling out the cause(s) of truly elevated MCHC (marked drepanocytosis [sickle cells], marked spherocytosis, and/or possibly marked acanthocytosis). Smears from lipemic blood often reveal some hazy RBCs and some damaged WBCs (primarily neutrophils, bands, and eosinophils) appearing as cells without a cell wall [8].

Although there are a few ways to obtain reliable results on such specimens, in our opinion, a simple and practical way is to reanalyze the specimen in the analyzer after replacing the plasma with an equal amount of an isotonic solution (preferably the diluent utilized in the analyzer) [6, 7, 9, 10]. We describe the plasma replacement procedure utilized by the clinical laboratory at Thomas Jefferson University Hospital (Philadelphia, PA, USA) below.

Centrifuge the blood specimen at 3,500 rpm for 10 min. Manually mark the plasma meniscus level on the centrifuged specimen tube, and using a disposable pipette, aspirate out as much of the plasma as possible without disturbing the buffy coat and transfer it into an empty tube. Substitute the plasma in the specimen tube with an isotonic solution (the diluent used in the analyzer or normal saline) up to the plasma meniscus level mark. Mix well manually and/or on a rotator and rerun the analysis. The CBC results obtained from the rerun after plasma replacement are considered reliable if the WBC, RBC, and PLT counts match with those of the initial run (within between-run reproducibility limits). In case of a discrepancy between the rerun and initial results of WBC, RBC, and/or PLT counts, the reliable results from the initial run (WBC, RBC, and PLT counts, Hct, MCV, and RDW) may be reported along with the rerun results of Hb, MCH, and MCHC.

Another approach utilized by some laboratories to obtain reliable results is to measure the plasma Hb concentration and calculate the correct blood Hb concentration using the following formula [1]:

Correct Hb=lipemic blood Hb−(1−Hct)×lipemic plasma Hb, and then recalculate the MCH and MCHC using the standard formulas:

Alternatively, one may measure the Hb concentration using a point-of-care analyzer (HemoCue, Ängelholm, Sweden), which is unaffected by lipemia, and then recalculate the MCH and MCHC [7].

Another simple approach for lipemic specimens, though not yet validated or reported in the literature, is to dilute an aliquot of the specimen with an isotonic diluent by an appropriate factor (e.g., 1 : 5) and rerun the analysis to obtain reliable results. This approach may or may not yield reliable results, depending on the degree of hyperlipidemia. If it works, the WBC, RBC, Hb, Hct, and PLT results should be appropriately corrected to account for the dilution. The MCV, MCH, MCHC, and RDW values are unaffected by the dilution and do not require correction.

If for some reason neither of the above approaches can be applied, one may choose to report only the reliable results, i.e., WBC, RBC, and PLT counts, Hct, MCV, and RDW and append a comment “accurate Hb, MCH, and MCHC are not obtained due to lipemia” [7].

Although never observed by the authors, lipemia-associated pseudoerythrocytosis has been reported [11].

RBCs may lyse in vivo in cases of autoimmune hemolytic anemia, hereditary spherocytosis, and sickle-cell disease or in vitro due to an inappropriate specimen collection process, inappropriate storage, and/or transport conditions [12, 13]. The indicators for in vivo hemolysis include a clinical diagnosis of hemolytic anemia, increased indirect bilirubin, decreased or absent haptoglobin, reticulocytosis, and microscopic results of increased polychromasia and/or the presence of spherocytes, schistocytes, and/or sickle RBCs. The indicators for in vitro hemolysis include normal reticulocyte count and parallel increases in potassium, lactate dehydrogenase, and AST concentrations corresponding to the serum or plasma Hb concentration. Blood specimens from patients with in vivo hemolysis yield correct automated CBC results but with higher than normal MCH and MCHC, because the Hb concentration represents the sum of cellular and plasma Hb concentrations. In vitro hemolysis may cause a falsely lower RBC count and Hct concentration and falsely higher MCH and MCHC [14]. A falsely higher PLT count may also be generated if RBC ghosts remaining after hemolysis are counted as PLTs by the analyzer [14]. Mildly elevated MCHC (typically <39 g/dL or <390 g/L) is considered suspicious for hemolysis (in vivo and in vitro). In our opinion, the automated CBC results may be reported without any correction/modification but with a comment “specimen hemolyzed, results may be affected” appended to at least one of the affected parameters (e.g., MCHC) only in cases where moderate or marked hemolysis is evident in the centrifuged or settled specimen tube or the spun micro-Hct. Alternatively, one may choose to report only the reliable results of WBC count, Hb, MCV, RDW, and blood smear-verified or estimated PLT count.

The total bilirubin concentration may be increased in several conditions, including liver disease (e.g., viral hepatitis or cirrhosis), hemolytic anemia, Gilbert’s syndrome, and gallstones. Bilirubin concentrations ≤25 mg/dL (≤425 μmol/L) generally do not adversely affect the results of any of the automated CBC parameters [15]. However, bilirubin concentrations of 25–35 mg/dL (425–600 μmol/L) may cause spectral interference in Hb measurement and result in falsely higher Hb, MCH, and MCHC. Plasma with an increased bilirubin concentration appears icteric (bright yellow). The analyzer may generate an Hb interference flag along with the elevated MCHC. To obtain reliable results, one may dilute the specimen by an appropriate factor (generally in the range of 1 : 2 to 1 : 5) with an isotonic solution (preferably the diluent used in the analyzer) and rerun the analysis. Before reporting, the results of WBC count, RBC count, Hb, Hct, and PLT count from the rerun should be appropriately corrected to account for the dilution. The MCV, MCH, MCHC, and RDW values do not require correction.

Cold-reactive (i.e., reactive at temperatures <37°C) IgM antibodies are typically associated with cytomegalovirus infection, mycoplasma pneumonia, and cold agglutinin disease. These antibodies generally cause RBC autoagglutination (RBC clumping), which interferes with the measurement of RBC-associated CBC parameters and yields falsely lower RBC count and Hct and falsely higher MCV, MCH, and MCHC [16]. Sometimes, WBCs may get trapped in the RBC agglutinates and therefore not be counted by the analyzer, resulting in a falsely lower WBC count. RBC agglutination is generally noted upon microscopic examination of the blood smear (Fig. 2) but may also be visually evident on the interior wall of the specimen tube. Among the various approaches recommended for obtaining reliable results, a common practice is to incubate the blood specimen at 37°C, typically for 10–15 min, and immediately rerun the analysis [16–18]. This approach generally yields accurate results of all CBC parameters. A blood smear made promptly after the incubation should be examined to confirm the absence of RBC agglutination. If this approach fails to yield accurate results, one may choose to request a new specimen to be collected and maintained at 37°C until analyzed or perform a micro-Hct and calculate all other RBC parameters (Hb, RBC count, MCV, MCH, and MCHC) using the standard formulas based on conventional units of measurement (Hb=Hct÷3, RBC=Hb÷3 or Hct÷9, MCV=Hct ×10÷RBC, MCH=Hb×10÷RBC, and MCHC=Hb×100÷Hct), particularly if the blood smear reveals normocytic and normochromic RBCs.

WBC clumping is an infrequently observed phenomenon that may involve one or more cell types [19-22]. The cell clumps are often too large to be counted, yielding a falsely lower WBC count. Clumps of granulocytes (Fig. 3) have occasionally been observed in the blood smears of patients with infection, cirrhosis, autoimmune disorder, uremia, immunosuppression, or various malignancies [21-26]. Clumps of lymphocytes have occasionally been observed in the blood smears of patients with lymphoproliferative disorders [21, 22]. The cause of WBC clumping may be multifactorial, including the presence of leukoagglutinins, which may be cold-reactive (at temperatures <37°C) and/or EDTA-dependent [19, 22-27]. To obtain reliable results, one may attempt any or all of the following approaches because none of them yields reliable results in all cases [19-27].

Irrespective of the method selected to obtain reliable results, it is important to examine a blood smear prepared after the rerun to ensure the absence of WBC clumping before reporting. The results are then reported with an appropriate comment (e.g., “WBC clumps noted,” “kanamycin added,” “vortexed,” “incubated,” or “citrated blood specimen”) appended to the WBC count. If all attempts fail, one may have to report “unable to obtain reliable WBC count due to WBC clumping.”

A falsely low PLT count, referred to as pseudothrombocytopenia, is not uncommon in clinical laboratories processing EDTA-anticoagulated blood specimens for CBC [28, 29]. The most common cause of PLT clumping is the presence of EDTA-dependent PLT antibodies/agglutinins [28-31]. A review of the analyzer-generated flag(s) and PLT and WBC histograms often points to the possibility of PLT clumps, but microscopic examination of a blood smear will confirm their presence (Fig. 4) [31, 32]. The PLT clumps may vary in size but often are outside the PLT counting threshold settings of the analyzer and therefore are excluded from the PLT counts, resulting in a falsely lower PLT count. Medium- and large-sized PLT clumps may be counted as WBCs, resulting in a falsely higher WBC count [33, 34]. One way to obtain reliable counts on such a specimen is to vortex the specimen for 1–2 min immediately before rerunning the analysis. Vortexing breaks up the PLT clumps in approximately 50% of such specimens and does not interfere with the measurement of any of the other basic CBC parameters [35]. Examining a blood smear prepared immediately after the vortexing is important to confirm the absence of clumps before reporting the results. Another commonly employed approach to obtaining reliable results is to request a new specimen properly collected in a citrated tube (blue-capped tube used for coagulation tests) [31]. Before reporting the result obtained with the citrated tube, multiply it with 1.1 to account for the dilution factor (based on the ratio of nine parts blood and one part anticoagulant in liquid form in the citrated tube), and prepare and examine a blood smear to ensure the absence of PLT clumps. A CBC can also be performed on the citrated blood specimen, and the results can be reported after multiplying the selected parameter results (WBC count, RBC count, Hb, Hct, and PLT count) by the dilution factor of 1.1. The MCV, MCH, MCHC, and RDW values do not require correction. PLT clumping may also occur in citrated specimens in some cases. Other means utilized by some laboratories to obtain reliable PLT counts in such cases include (i) collecting and maintaining the anticoagulated blood at 37°C until analysis, (ii) using an alternative anticoagulant, such as acid citrate dextrose, citrate-pyrophosphate-Tris mixture, or magnesium sulfate, to collect blood, and (iii) adding an aminoglycoside drug (amikacin or kanamycin) to the EDTA-anticoagulated blood specimen before performing the CBC [32]. Concomitant pseudoleukocytosis, if caused by PLT clumps, will also resolve with the approach used to resolve the pseudothrombocytopenia owing to PLT clumping/agglutination [36]. A reliable WBC count estimate can be obtained from the blood smear.

Increased concentrations of paraproteins (IgM, IgG, and IgA), as observed in cases of plasma cell and lymphoplasmacytic disorders, may interfere with Hb measurement and result in falsely higher Hb, MCH, and MCHC [37]. Analyzer-generated flag(s), delta check failures, elevated MCHC, and an unexpected Hb result are helpful indicators. To obtain reliable results, one can perform plasma replacement before rerunning the analysis or measure the plasma Hb and calculate the true Hb, MCH, and MCHC as described above for lipemic specimens.

Although never observed by the authors, paraprotein-associated falsely higher WBC and PLT counts have been reported [38]. Plasma replacement before rerunning the analysis will yield reliable cell counts.

Cryoglobulins and cryofibrinogen are plasma proteins that precipitate on cooling (to temperatures <37°C) and redissolve upon warming (to 37°C). Clinical conditions associated with cryoglobulinemia and/or cryofibrinogenemia include various benign and malignant conditions, such as infections (particularly, hepatitis C), autoimmune disorders, plasma cell disorders, lymphoproliferative disorders, and carcinomas [39]. Their presence may be suspected from analyzer-generated flag(s), on observing turbid plasma (Fig. 5) in the specimen tube kept at room temperature or in the refrigerator, and/or upon noticing pale amorphous precipitates (Fig. 6), globules, and/or crystalline material on microscopic examination of a blood smear [40]. Cryoproteins may result in falsely higher WBC and/or PLT counts in various analyzers [40-46]. To obtain reliable results, one may incubate the blood specimen at 37°C for 10-20 min immediately before rerunning the analysis or perform plasma replacement using a warm isotonic diluent maintained at 37°C. Some laboratories choose to draw a new blood specimen and maintain it at 37°C until analysis to obtain reliable results.

Bacterial, fungal (yeast), and malarial parasites, when present in the blood at very high concentrations, may cause falsely higher PLT and/or WBC counts on various analyzers [47-52]. The presence of individual bacterial cells (particularly, extracellular bacteria) is more likely to cause a falsely higher PLT count, whereas the presence of bacterial or fungal cell clusters or large fungal cells is more likely to cause a falsely higher WBC count because of their respective sizes. Large fungal cells (e.g., certain Candida and cryptococcal species) may mimic small lymphocytes and thus adversely affect automated DIFF. Although not observed by the authors, RBCs infected with Plasmodium falciparum trophozoites caused falsely higher PLT counts in some analyzers [52]. Organisms may be present either as a contaminant (bacteria and yeast) in the specimen tube or due to an actual infection (bacteremia, fungemia, and malaria). Analyzer-generated flag(s), histograms, and scattergrams, delta check failures, unexpected results, and clinical diagnosis are helpful indicators. Microscopic examination of a blood smear and/or blood culture report will confirm the presence of microorganisms. To obtain reliable results, one may choose to report estimated WBC and PLT counts obtained from a blood smear or request a new, properly collected specimen, particularly if contamination is suspected.

Blood glucose concentrations ≥600 mg/dL (≥33 mmol/L) may cause falsely higher MCV and Hct and falsely lower MCHC [53]. Such high glucose concentrations, though rarely observed in patients with diabetes, is generally the result of contamination of a blood specimen with glucose-containing intravenous fluid. The combination of elevated MCV and decreased MCHC is a reliable indicator of a high blood glucose concentration affecting the CBC results. Reviewing the chemistry test results, if available, will confirm the high glucose concentration. Microscopic examination of a blood smear will reveal macrocytic, normochromic RBCs (Fig. 7). To obtain reliable results, one may dilute a small aliquot of the specimen with the isotonic diluent and incubate it at room temperature, typically for 10 min, and then rerun the analysis. The results of the rerun are to be corrected to account for the dilution before reporting. Alternatively, one can run a micro-Hct, which is not affected by a high blood glucose concentration, and recalculate the MCV and MCHC using standard formulas:

Falsely higher MCV and Hct along with falsely lower MCHC have been obtained on blood specimens left at room temperature for one to four days before being processed for CBC on an automated analyzer [54]. One may choose to reject such specimens or report only the WBC, RBC, Hb, MCH, and PLT results after validating the WBC and PLT by smear review. To the best of our knowledge, there exists only one report of an in vitro study of blood specimens collected from healthy humans that revealed falsely low WBC counts associated with increasing blood glucose concentrations [55].

Blood specimens drawn from a site above the intravenous line without stopping the infusion are often diluted with the transfusion fluid [56]. The dilution effect will manifest in the form of falsely low WBC, RBC, Hb, Hct, and PLT counts. Such low counts are accurate for the specimen but unreliable for patient care because of the dilution effect. Delta check failures, unexpected results, and chemistry results, if available, often point to the dilution effect. To obtain reliable results, it is important to request a new, properly collected specimen.

The contamination of blood with subcutaneous fat tissue during a difficult/traumatic venipuncture, though rare, may cause a falsely higher WBC count besides affecting the DIFF in some analyzers [57, 58]. Analyzer-generated flag(s) and the WBC scattergram, delta check failures, and unexpected result(s) are helpful indicators. Microscopic examination of a blood smear stained with a Romanowski stain may reveal fat globules in the form of round/ovoid empty spaces. These globules stain orange-red with a fat stain, such as Sudan III. To obtain reliable results, one may choose to replace the automated WBC count with an estimated WBC count obtained from a blood smear and the automated DIFF results with manual DIFF results or request a new, properly collected specimen.

If a blood specimen that contains fibrin clumps is inadvertently run in the analyzer, it may yield a falsely higher WBC count or clog the counting aperture or flow cell, yielding no or erroneous CBC results [59, 60]. Analyzer-generated flag(s) and histograms may provide a clue to the presence of fibrin clumps, but microscopic examination of a blood smear will confirm their presence. Such a blood specimen is generally considered unsuitable for performing a CBC, and one often chooses to request a new, properly collected blood specimen. The authors have experienced that, sometimes, only the PLT count is adversely affected, and the results of all other CBC parameters are comparable to previously obtained results.

The presence of small clots in the specimen may cause inaccurate result(s) for any one or more CBC parameters, depending on the number of small clots aspirated by the sampling probe of the analyzer, or no results due to clogging of the counting aperture or flow cell. Typically, all cell counts and Hb are falsely lower [1]. Delta check failures, unexpected results, and review of analyzer-generated flags, histograms, and scattergrams are helpful in recognizing such unreliable CBC results. A properly collected new blood specimen is needed to obtain reliable CBC results.

Fragments of RBCs, commonly referred to as schistocytes, may take various forms, including helmet cells, bite cells, horn cells, triangular cells, and microspherocytes. Clinical conditions associated with the presence of RBC fragments include disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, malignant hypertension, prosthetic heart valve, severe burns, metastatic carcinoma, HELLP syndrome (hemolysis, elevated liver enzymes, and low PLTs), hereditary pyropoikilocytosis, and march hemoglobinuria. The fragment size is variable but often falls in the PLT counting range of many analyzers. Consequently, they are frequently counted as PLTs, resulting in a falsely higher PLT count [61-64]. One of the authors (GG) has observed a case of pseudothrombocytosis associated with marked RBC fragmentation in a blood specimen inadvertently left over a heat radiator immediately after collection, presumably for a short period (few min). Analyzer-generated flag(s), RBC and PLT histograms, and unexpected PLT results are helpful indicators of falsely high PLT count. The presence of RBC fragments (Fig. 8) is confirmed by a blood smear microscopic examination. For specimens revealing a high number of schistocytes (graded as ≥2+) on the blood smear, one may choose to replace the automated PLT count with an estimated PLT count obtained from the blood smear utilizing the predefined laboratory or standard criteria or perform a manual PLT count using phase microscopy. Optical PLT counting with or without fluorescence may also yield a reliable PLT count in some cases.

Blood specimens revealing extreme microcytosis (MCV <60 fL, particularly if MCV <50 fL) may contain some RBCs that are too small (below the RBC counting threshold of the analyzer) to be counted as RBCs but are within the PLT counting threshold and hence are counted as PLTs, particularly in analyzers utilizing impedance technology [65, 66]. The outcome is a falsely higher PLT count and possibly, a falsely higher MPV. The effects on RBC parameters (falsely lower RBC count and Hct and falsely normal MCV) are often not clinically significant and may be reported without any correction but with a comment “extremely small RBCs present, result may be affected” appended to one of the affected parameters, preferably the MCV, only after confirming their presence in a blood smear. Combined presence of extremely small RBCs and RBC fragments (Fig. 9) may, at times, result in a falsely higher RBC count, depending on the size and relative proportion of the RBC fragments. The effects on the PLT count and MPV may be clinically significant and require resolution. The PLT count estimated from a blood smear should replace the unreliable automated PLT count or one may choose to perform the PLT count using an alternative automated approach (such as an optical method with or without fluorescence), if available [67]. The PLT count obtained by the optical method may or may not be reliable and therefore requires verification by a PLT estimate from a blood smear. The MPV and RBC count should either not be reported or reported with an appropriate comment.

Although not observed by the authors, it has been reported that some abnormal RBCs, i.e., those containing Hb C or S, may not lyse well with the lysing reagent utilized in some analyzers [68]. The non-lysed RBCs may be counted as WBCs and create turbidity causing interference in Hb measurement, ultimately leading to falsely higher WBC count, Hb, MCH, and MCHC. Analyzer-generated flag(s) and the WBC scattergram, microscopic examination of a blood smear, clinical diagnosis, and results of Hb variant analysis are helpful indicators of this phenomenon. The ways to obtain reliable results include increasing the amount of lysing reagent, prolonging the lysis time, and/or preferably diluting the blood specimen and rerunning the analysis.

A WBC count of ≥100,000/µL is generally referred to as hyperleukocytosis. Clinical conditions associated with hyperleukocytosis include chronic leukemias, acute leukemias, and occasionally, severe reactive conditions. Hyperleukocytosis may cause turbidity interference in Hb measurement and result in falsely higher Hb, MCH, and MCHC. Depending on the degree of hyperleukocytosis, falsely higher results may also be observed for the RBC count, MCV, and Hct, all of which may be clinically significant or insignificant [69, 70]. To obtain reliable results, one may dilute the blood specimen with an isotonic fluid (preferably the diluent used in the analyzer) by an appropriate factor and rerun the analysis. Before reporting, the Hb, Hct, and WBC, RBC, PLT count results from the rerun should be appropriately corrected to account for the dilution. The MCV, MCH, MCHC, and RDW values do not require correction.

Giant PLTs are PLTs of the size of normal RBCs or larger (≥8 µm). Clinical conditions associated with the presence of giant PLTs in the blood include chronic myeloproliferative neoplasms (particularly, primary myelofibrosis and essential thrombocythemia) and various inherited macrothrombocytopenias, such as May–Hegglin anomaly and Bernard–Soulier syndrome. When present in high numbers, giant PLTs frequently result in a falsely lower PLT count and occasionally may result in a falsely higher WBC count [71, 72]. The RBC parameters (RBC count, MCV, Hct, MCH, and MCHC) may also be affected, but these changes are generally not clinically significant and not worth spending time to correct. The presence of giant PLTs is often suspected by review of analyzer-generated flag(s), histograms, and scattergrams and confirmed by microscopic examination of a blood smear (Fig. 10). To obtain a reliable PLT count, one may resort to manual counting in a hemocytometer using phase microscopy or preferably, report an estimated PLT count obtained from a blood smear according to the generally recommended or laboratory’s predefined criteria. Similarly, an estimated WBC count is reported in case of an unreliable automated WBC count as evidenced by a discrepancy between the automated and estimated counts.

Cytoplasmic fragments of leukemic cells are occasionally observed on microscopic examination of the peripheral blood smears of some patients diagnosed as having acute leukemia or hairy cell leukemia [73-76]. These may mimic PLTs, RBCs, and/or WBCs depending on their size, and when present in high numbers (graded as ≥2+), may result in falsely higher respective automated counts. Often, they are small and counted as PLTs, resulting in a falsely higher automated PLT count [73-76]. Their effect on the RBC count, if present, is generally clinically insignificant, and their effect on the WBC count may be significant in some cases. Although the presence of cytoplasmic fragments of leukemic cells is generally detected during the microscopic examination of a blood smear, one may suspect the false nature of the automated counts by reviewing the analyzer-generated flags and histograms, delta check failures, and/or by observing a discrepancy between the obtained and expected results. The PLT and WBC counts estimated from a blood smear according to the generally recommended or laboratory’s predefined criteria should replace the respective automated cell counts. The criteria used in the clinical laboratory at Thomas Jefferson University Hospital are provided below:

^aTo obtain the average number of cells per field, one generally counts the respective cells in each of 10 microscopic fields in different parts of the readable area of the smear and then divides the total number by 10. Reliable estimated counts can only be obtained if the blood smear is of acceptable quality and is devoid of clumps of the respective cells.

An estimated RBC count is neither recommended nor necessary.

Adherence of PLTs to WBCs, primarily neutrophils and bands, is generally referred to as PLT satellitosis or PLT satellitism [77]. PLT satellitosis may be an immunologic or non-immunologic phenomenon that occurs mainly in EDTA-anticoagulated blood specimens and may cause a falsely lower PLT count [78, 79]. Analyzer-generated flag(s), histograms, and scattergrams, delta check failures, and unexpected results are helpful indicators, but microscopic examination of a blood smear will confirm the presence of satellitosis and its adverse effects on the cell counts. To obtain reliable results, one may choose to obtain citrated blood to perform the CBC or vortex the EDTA-anticoagulated specimen before rerunning the analysis [77-80].

NRBCs may be present in the blood of premature newborns and in several clinical conditions, including hemolytic disease of the newborn, hemolytic anemias, pure erythroid leukemia, chronic myeloproliferative neoplasms, and myelodysplastic syndromes [81]. NRBCs are counted along with WBCs by many, if not all, automated analyzers; the outcome is a falsely higher WBC count. Analyzer-generated flag(s) and the WBC scattergram often highlight the possible presence of NRBCs, which may be confirmed by microscopic examination of a blood smear (Fig. 11). Many analyzers are capable of reporting a WBC count that has automatically been corrected for the presence of NRBCs [82, 83]. If not, the uncorrected automated WBC count may be manually corrected using the following formula:

A variable number of megakaryocytes (megakaryoblasts, naked nuclei of megakaryocytes, and/or micromegakaryocytes) may be seen in the blood smears of patients with suspected or confirmed diagnosis of chronic myeloproliferative neoplasms, myelodysplastic syndromes, and acute megakaryoblastic leukemia [84, 85]. Rarely, an occasional megakaryocyte may be seen in peripheral blood smears of premature newborns or adults with non-malignant conditions [86]. When present, megakaryocytes will be included in the WBC count by the analyzer, resulting in a falsely higher WBC count. To the best of our knowledge, none of the current CBC analyzers can differentiate megakaryocytes from WBCs and consequently, the automated WBC count has to be manually corrected for their presence using the below formula. In the clinical laboratory at Thomas Jefferson University, manual correction is conducted only if megakaryocytes are present in high numbers (arbitrarily defined as more than 10 per 100 WBCs).

If both NRBCs and megakaryocytes are present in the blood, both will be included in the automated WBC count. Upon confirming their presence in a blood smear, one may correct the uncorrected automated WBC count for their presence, particularly when present in high numbers (arbitrarily defined as more than 10 NRBCs and megakaryocytes per 100 WBCs) using the following formula:

The presence of carcinoma cells in blood (carcinocythemia) is a rarely encountered phenomenon. As none of the current automated analyzers can differentiate carcinoma cells from WBCs, the former will be counted along with the latter in the total WBC. The outcome will be a falsely higher WBC count, which may be clinically significant or insignificant depending on the degree of carcinocythemia. A reliable WBC count may be obtained by correcting the automated uncorrected WBC count using the following formula: